AD	

GRANT NUMBER DAMD17-97-1-7201

TITLE: Expression of the Estrogen-Regulated pS2 Gene in MCF-7 Human Breast Cancer Cells

PRINCIPAL INVESTIGATOR: Lawrence N. Petz, Ph.D.

CONTRACTING ORGANIZATION: University of Illinois

Champaign, Illinois 61820

REPORT DATE: August 1999

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command

Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for public release;

distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20001005 039

## REPORT DOCUMENTATION PAGE

Form Approved OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.

1. AGENCY USE ONLY (Leave blank	2. REPORT DATE August 1999		3. REPORT TYPE AND DATES COVERED Annual (1 Aug 98 - 31 Jul 99)	
4. TITLE AND SUBTITLE			5. FUNDING NUMBERS	
Expression of the Estrogen-Regul	ated pS2 Gene in MCF-7 H	uman Breast Cancer Cells	DAMD17-97-1-7201	
6. AUTHOR(S)				
Petz, Lawrence N., Ph.D.				
7. PERFORMING ORGANIZATION NA	ME(S) AND ADDRESS(ES)		8. PERFORMING ORGANIZATION REPORT NUMBER	
University of Illinois Champaign, Illinois 61820			ner om Nowben	
9. SPONSORING / MONITORING AGI	ENCY NAME (C) AND ADDRESS	C/EC/	10 SPONICOPING / MONITOPING	
		5(E5)	10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
U.S. Army Medical Research and Fort Detrick, Maryland 21702-50	Materiel Command			
11. SUPPLEMENTARY NOTES				
12a. DISTRIBUTION / AVAILABILITY	STATEMENT		12b. DISTRIBUTION CODE	
Approved for public release; distr	ibution unlimited			
13 ABSTRACT (Maximum 200 wor	del			

In vivo footprinting was utilized to examine the estrogen-responsive pS2 gene in MCF-7 human breast cancer cells. Estrogen treatment resulted in an extensive region of protection within and adjacent to the pS2 estrogen response element (ERE). The antiestrogens 4-hydroxytamoxifen and ICI 182,780 each produced distinct protection patterns of the pS2 ERE. The TATA and CAAT sequences were protected and flanked by hypersensitive sites in the presence and absence of hormone in MCF-7 cells but not in estrogen receptor (ER)-negative MDA MB 231 cells. To aid in future identification of proteins bound to these elements, in vitro footprinting experiments were performed utilizing purified ER and nuclear extracts from estrogen-treated MCF-7 cells. Results of in vitro DNase I footprinting experiments paralleled the protection patterns of in vivo footprinting experiments. The CAAT box was minimally protected with hypersensitive sites surrounding both the TATA and CAAT boxes. Our studies suggest that proteins present in nuclear extracts from estrogen-treated MCF-7 cells bind to pS2 regulatory elements in vitro in a fashion that is very similar to binding in vivo. These results will help to identify proteins involved in regulation of the pS2 gene and provide a model system to define how estrogen-responsive genes are regulated.

	ivo footprinting, in vi	, ,	15. NUMBER OF PAGES 9
MCF-7, tamoxifen, estrogen, pS2, gene transcription			16. PRICE CODE
17. SECURITY CLASSIFICATION OF REPORT	18. SECURITY CLASSIFICATION OF THIS PAGE	19. SECURITY CLASSIFICATION OF ABSTRACT	20. LIMITATION OF ABSTRACT
Unclassified	Unclassified	Unclassified	Unlimited

# FOREWORD

Where copyrighted material is quoted, permission has been obtained to use such material.  Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.  Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.  In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and use of Laboratory Animals of the Institute of Laboratory Resources, national Research Council (NIH Publication No. 86-23, Revised 1985).  For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.  In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.  In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.  In the conduct of research involving hazardous organisms,	Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.
distribution is quoted, permission has been obtained to use the material.  Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.  In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and use of Laboratory Animals of the Institute of Laboratory Resources, national Research Council (NIH Publication No. 86-23, Revised 1985).  For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.  In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.  In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.  Ml In the conduct of research involving hazardous organisms,	
this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.	distribution is quoted, permission has been obtained to use the
adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and use of Laboratory Animals of the Institute of Laboratory Resources, national Research Council (NIH Publication No. 86-23, Revised 1985).	this report do not constitute an official Department of Army endorsement or approval of the products or services of these
In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.  In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.  In the conduct of research involving hazardous organisms,	adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and use of Laboratory Animals of the Institute of Laboratory Resources, national
the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.  In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.  In the conduct of research involving hazardous organisms,	$\sqrt{}$ For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.
investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.  In the conduct of research involving hazardous organisms,	the investigator(s) adhered to current guidelines promulgated by
	investigator(s) adhered to the NIH Guidelines for Research
the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.	the investigator(s) adhered to the CDC-NIH Guide for Biosafety in

# TABLE OF CONTENTS

FRONT COVER	1
STANDARD FORM 298	2
FOREWORD	3
TABLE OF CONTENTS	4
INTRODUCTION	5
BODY	6
APPENDIX	c

## INTRODUCTION

Estrogen is a hormone of critical importance in the development and maintenance of normal reproductive tissues. Estrogen acts through an intracellular estrogen receptor (ER), which interacts with estrogen response elements (EREs) in target genes to initiate changes in transcription. One estrogen-responsive gene, which is expressed in many breast cancer cells, but not in normal mammary cells is the pS2 gene. The pS2 gene contains all of the elements of a classic hormone-responsive gene: an imperfect ERE (differs from the consensus ERE by a single nucleotide in the 3' half site), a TATA box, and a CAAT box. Our goal is to gain a better understanding of how estrogen-responsive genes are regulated in living cells. To do this we have utilized *in vivo* ligation mediated polymerase chain reaction footprinting to examine the regulatory elements of the pS2 gene in intact MCF-7 cells. To aid in the future identification of proteins bound to these elements, *in vitro* footprinting experiments were performed utilizing purified ER and nuclear extracts from estrogen-treated MCF-7cells.

#### **BODY**

We have addressed several of the Technical Objectives listed in the original grant. These objectives are listed below:

Task 1-2: DNase I treatment and LMPCR conditions that result in clear footprinting ladders have been optimized to examine the pS2 gene.

Task 3: K1 cells were treated with ethanol or 17β-estradiol, DNase I treated and genomic DNA isolated. *In vivo* footprints were detected on the noncoding strand in the regions of the TATA and CAAT boxes. We have designed a set of nested primers to examine the coding strand in this region. In addition to these objectives stated in our original grant, we extended our investigations to examine dimethlysulfate *in vivo* footprints on the noncoding strand in the regions of the TATA and CAAT boxes.

Task 4: K1 cells were treated with trans-hydroxytamoxifen or ICI 182,780 and DNase I treated, but the regions of the TATA and CAAT boxes have not yet been examined.

Task 5-7: K1 cells were treated with ethanol, 17β-estradiol, trans-hydroxytamoxifen or ICI 182,780 and DNase I treated. Conditions have been optimized and *in vivo* footprints were detected with one set of nested primers designed to examine the noncoding strand of the pS2 ERE. We are in the process of optimizing conditions to examine the coding strand of the pS2 ERE using a second set of nested primers. In addition to these objectives stated in our original grant, we extended our investigations to examine dimethlysulfate *in vivo* footprints on the noncoding strand in the region of the pS2 ERE.

We have further extended our investigations to compare the time frame of pS2 mRNA expression to events occurring at the level of the gene. Northern blot analysis was utilized to

detect the relative levels of pS2 mRNA. The level of MCF-7 pS2 mRNA increased 16-fold after a 24 hours exposure to estrogen. These findings demonstrated that the pS2 gene was essentially inactive in the absence of estrogen, but responded robustly to estrogen treatment.

Examining the regulatory elements of the pS2 gene utilizing *in vivo* DNase I footprinting demonstrated that 24 hour estrogen treatment of MCF-7 cells resulted in extensive protection within and adjacent to the pS2 ERE. Interestingly treatment of MCF-7 cells with the antiestrogens 4-hydroxytamoxifen or ICI 182,780 each produced distinct protection patterns of the pS2 ERE. Also, the TATA and CAAT sequences were protected and flanked by hypersensitive sites in the presence and in the absence of hormone in ER-positive MCF-7 cells but not ER-negative MDA MB 231 cells. These findings indicate that the ER is involved not only in mediating the cellular response to hormone, but may also be involved in organization of the proximal promoter in the absence of hormone.

We have extended our studies to allow us to identify proteins interacting with the pS2 ERE. To determine whether proteins present in MCF-7nuclear extracts could bind to the pS2 ERE, gel mobility shift assays were carried out. When DNA fragments containing the pS2 ERE were combined with purified ER or nuclear extracts prepared from estrogen-treated MCF-7 cells, a major protein-DNA complex was formed. Since we anticipated that ER might bind to this region, antibodies to this proteins was included in separate binding reactions. The major protein-DNA complex was supershifted by the ER-specific antibody, H151, suggesting that ER bound efficiently to the pS2 ERE.

To aid in the future identification of proteins associated with the ERE bound ER, *in vitro*DNase I footprinting experiments were utilized, and the resulting protection patterns compared to

our *in vivo* footprinting experiments. DNA fragments, each containing the pS2 ERE, or the pS2 TATA box and CAAT box were incubated with increasing amounts of estrogen-treated MCF-7 nuclear extract or increasing amounts purified ER and exposed to DNase I. The resulting protection patterns were very similar to the protection patterns of our *in vivo* footprinting experiments. The pS2 perfect ERE half site was protected at the lowest protein concentrations followed by protection of the imperfect ERE half site at the highest protein concentrations. The CAAT box showed minimal protection with hypersensitive DNase I cleavage sites surrounding both the TATA and CAAT boxes. Because of the mirrored protection patterns in both our *in vitro* and *in vivo* footprinting experiments, it seems likely that proteins present in nuclear extracts from estrogen-treated MCF-7 cells bind to the pS2 regulatory elements in a fashion that is very similar to binding of proteins in intact MCF-7 cells. These results will help in identifying proteins involved in the transcriptional regulation of the pS2 gene and increase our understanding of estrogen-regulation genes.

### **APPENDIX**

Key research accomplishments:

- In vivo DNase I footprinting experiments indicate the events occurring at the level of the pS2 gene are well coupled to the levels of pS2 mRNA in estrogen-treated MCF-7 human breast cancer cells.
- In vivo DNase I footprinting experiments demonstrate that the pS2 ERE is strongly protected after estrogen treatment and remains occupied for at least 24 hours after treatment.
- In vivo DNase I footprinting experiments demonstrate that antiestrogens mediate their effects by promoting the association of proteins with unique regions of the pS2 promoter.
- In vivo DNase I footprinting experiments demonstrate that the TATA and CAAT sequences are occupied and are flanked by hypersensitive sites in the presence and in the absence of estrogentreatment.
- Purified ER and ER present in estrogen-treated MCF-7 cells can bind to the pS2 ERE, and is supershifted by an ER-specific antibody.
- In vitro DNase I footprinting experiments result in protection patterns that are very similar to the protection patterns seen in in vivo footprinting experiments.